Articles By Susan Shenoi, MD, MS

FDA,approved,stamp,blue

Emapalumab Approved for MAS in Still’s

By Susan Shenoi, MD, MS

On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with inadequate response or intolerance to glucocorticoids.

Read Article
scale decision balance question

Female Force

By Susan Shenoi, MD, MS

In medicine, a field where burnout is becoming the norm, there is much promotion of the idea of work-life balance. In reality, the scales between work and life aren’t really balanced. Is the potential for change on the horizon?

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Susan Shenoi, MD, MS
  • Susan Shenoi, MD, MS

  • Susan Shenoi, MD, MS, is an Associate Professor in the Division of Rheumatology, Department of Pediatrics at Seattle Children’s Hospital and Research Center, University of Washington, Seattle, WA. Dr. Shenoi is also the Clinical Director for Rheumatology and Director for the Seattle Cure JM Myositis Center of Excellence. Dr Shenoi’s research interests include epidemiologic and environmental research in juvenile idiopathic arthritis and systemic juvenile arthritis. Dr Shenoi is interested in integration and use of ultrasound in juvenile arthritis and is passionate about increasing awareness and improving outcomes of pediatric autoimmune diseases.  She is a member of CARRA (Childhood Arthritis Rheumatology and Research Alliance) and PRCSG (Pediatric Rheumatology Collaborative Study Group).

×